Cambridge drug developer Tiburio launches, targeting pituitary tumors with $31M
January 03, 2019 at 07:00 AM EST
New biotech Tiburio Therapeutics Inc. is hoping to use two drug compounds licensed from French drugmaker Ipsen to address difficult-to-treat pituitary tumors and rare endocrine diseases.
